Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Combo bests single therapy in metastatic RCC

Motzer RJ et al. GU Cancers Symposium Abstract 578

Key clinical point: The combination of atezolizumab and bevacizumab is more efficacious than single-agent sunitinib as first-line therapy for metastatic RCC.

Major finding: Among patients with PD-L1-positive disease, median investigator-assessed progression-free survival was 11.2 months with atezolizumab-bevacizumab and 7.7 months with sunitinib (hazard ratio, 0.74; P = .02).

Data source: A randomized phase 3 trial among 915 patients with treatment-naive advanced or metastatic RCC (IMmotion151 trial).

Disclosures: Dr. Motzer disclosed that he has a consulting or advisory role with Pfizer, Novartis, Eisai, Exelixis, and Merck, and that his institution receives research funding from Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Eisai, Novartis, and Genentech/Roche. The study was sponsored by Genentech/Roche.

Source: Motzer RJ et al. GU Cancers Symposium Abstract 578

Citation:

Motzer RJ et al. GU Cancers Symposium Abstract 578

This Week's Must Reads

Vanderbilt staging best for predicting overall survival in retroperitoneal sarcoma, Huggett B & Cates J. Modern Pathology; 5 Nov. 2018. https://www.nature.com/articles/s41379-018-0166-8

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027

DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.

ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.

Must Reads in Renal Cell Carcinoma

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027

DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.

ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.

SRS can effectively control brain metastases in patients with RCC, Wardak Z et al. Clin Genitourin Cancer. 2018 Nov 20. doi: 10.1016/j.clgc.2018.11.006.